IceTropin (somatropin, rDNA origin, for injection) is a polypeptide hormone of recombinant DNA origin. It has been demonstrated that somatropin is therapeutically equivalent to human growth hormone secreted by the pituitary gland. In children with inadequate endogenous growth hormone, somatropin stimulates linear growth and increases growth speed. IceTropin administration results in the increase in growth velocity and growth factor of I levels insulin-like (IFG-I), similar to that produced by hGH.
IceTropin is administrated intramuscular or subcutaneous daily, after mixing of lyophilized powder with 1-5 ml of water for injections, preferably in the evening before bedtime.
The dose is determined individually by the doctor, according to weight and body surface area.
Growth retardation in children due to inadequate secretion of endogenous growth hormone: the recommended dose is 0.5-0.7 IU/kg/week or 14-20 IU/m2/week. Sometimes can be used higher doses.
Gonadal dysgenesis (Turner syndrome): the recommended dose is 1.0 IU/kg/week or 28 IU/m2/week.
Chronic Kidney Disease: 30 IU/m2/week. May require higher doses if the growth rate is too small. May be necessary to adjust the dose after 6 weeks of treatment.
Growth hormone deficiency in adults: starting dose recommended is 0.125 IU/kg/week for about 4 weeks. The dose should be later adjusted depending on the adverse reactions and with determining factor of growth I insulin-like (IGF-I) in the blood serum as a measure of orientation.
The weekly dose should be divided into seven subcutaneous injections. To prevent lipoatrophy is recommended alternating the places of administration.
If a dose was missed, the next dose will not be doubled the next day, but will continue treatment according to the obtained regime of dosing.
After reconstitution with water for injections, the prepared solution is stable for up to 14 days, stored in a refrigerator [36°F to 46°F (2°C to 8°C)]. The reconstituted solution will not be frozen